Impact of liposomal amphotericin B on renal function in critically ill patients with renal function impairment;Impacto de anfotericina B liposomal en la función renal en pacientes críticos con la función renal deteriorada

Revista Espanola de Quimioterapia

Volumn 25, Issue 3, 2012, Pages 206-215

  Álvarez Lerma, Francisco ^a   Soriano, Mari Cruz ^b   Rodríguez, Montserrat ^c   Catalán, Mercedes ^d   Llorente, Ana María ^d   Vidart, Nieves ^e   Garitacelaya, María ^e   Maraví, Enrique ^f   Fernández, Elisabeth ^g   Alvarado, Francisco ^b   López, Marta ^h   Álvarez Sánchez, Bernabé ⁱ   Espinosa, Jesús ^j   Quintana, Elisabeth ^k  

^a Parc de Salut Mar ^*  (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL UNIVERSITARIO INFANTA LEONOR   (Spain)

^d HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^e HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^f Universidad Pública de Navarra   (Spain)

^g HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^h HOSPITAL UNIVERSITARIO MARQUÉS DE VALDECILLA   (Spain)

ⁱ HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^j HOSPITAL INFANTA CRISTINA   (Spain)

^k HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

more..

Author keywords

Critically ill patient; ICU; Liposomal amphotericin B; Nephrotoxicity; Tolerability

Indexed keywords

AMPHOTERICIN B LIPID COMPLEX; CREATININE;

ARTICLE; COMPARATIVE STUDY; CREATININE BLOOD LEVEL; CRITICALLY ILL PATIENT; DRUG TOLERABILITY; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MORTALITY; MULTICENTER STUDY; NEPHROTOXICITY; RETROSPECTIVE STUDY; RISK FACTOR; TREATMENT DURATION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CREATININE; CRITICAL ILLNESS; FEMALE; HUMANS; INFANT; KIDNEY; KIDNEY DISEASES; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MYCOSES; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84868517486     PISSN: 02143429     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Sabra R, Branch RA, Amphotericin B nephrotoxicity. Drug Saf 1990; 5:94-108.
2. Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex versus conventional amphotericn B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies-a randomized, controlled trial. Eur J Haematol 2004; 72:342-7.
3. Luke RG, Boyle JA. Renal effects of amphotericin B lipid complex. Am J Kidney Dis 1998; 31:780-5.
4. Sharkey PK, Graybill JR, Johnson ES, Hausrath SG, Pollard RB, Kolokathis A, et al. Amphotericin B lipid complex compared with amphotericin B in the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis 1996; 22:315-21
5. Miller CB, Waller EK, Klingemann HG, Dignani MC, Anaissie EJ, Cagnoni PJ, et al. Lipid formulations of amphotericin B preserve and stabilize renal functions in HSCT recipients. Bone Marrow Transplant 2004; 33:543-8.
6. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340:764-71.
7. Prentice HG, Hann IM, Herbrecht R, Aoun M, Kvaloy S, Catovsky D, et al. A randomized comparison of liposomal versus conventional amphoterin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98:711-8.
8. Leenders AC, Daenen S, Jansen RL, Hop WC, Lowenberg B, Wijermans PW, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the invasive fungal infections. Br J Haematol 1988; 103:205-12.
9. Cagnoni PJ, Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother 2002; 49:81-6.
10. Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. Clin Infect Dis 2000; 31:1155-63.
11. Ullmann AJ, Sanz MA, Tramarin A, Barnes RA, Wu W, Gerlach BA, et al. Prospective study of amphotericin B formulations in immunocompromised patients in 4 European countries. Clin Infect Dis 2006; 43:e29-38.
12. Garnacho-Montero J, León Gil C, Almirante B, Alvarez Lerma F, Cuenca Estrella M, Garcia Rodriguez JA, et al. Recomendaciones terapéuticas en el paciente crítico no neutropénico. Conferencia de Consenso. Conclusiones. Med Intensiva 2005 (Supl 3):43-52.
13. Ostrosky-Zeichner L, Pappas P. Invasive candidiasis in the intensive care unit. Crit Care Med 2006; 34:857-63.
14. Alvarez-Lerma F, Mariscal F, Quintana E, Rialp G, Diaz-Reganon J, Perez MJ, et al. Use of liposomal amphotericin B in critically ill patients: a retrospective, multicenter, clinical study. J Chemother 2009; 21:330-7.
15. Alvarez-Lerma F, Mariscal F, Quintana E, Rialp G, Diaz-Reganon J, Pérez San José MJ, et al. Impact of the administration of liposomal amphotericin B in patients with renal function impairment at initiation of treatment. J Chemother 2010; 22:285-7.
16. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med 1985; 13:818-29.
17. Walsh TJ, Hiemenz JW, Seibel NL, Perfect JR, Horwith G, Lee L, et al. Amphotericin B lipid complex for invasive fungal infections: analysis of safety and efficacy in 556 cases. Clin Infect Dis 1998; 26:1383-96.
18. Mehta R, Lopez-Berestein G, Hopfer R, Mills K, Juliano RL. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells. Biochim Biophys Acta 1984 14; 770:230-4.
19. Olsen SJ, Swerdel MR, Blue B, Clark JM, Bonner DP. Tissue distribution of amphotericin B lipid complex in laboratory animals. J Pharm Pharmacol 1991; 43:831-5.
20. Janoff AS, Boni LT, Popescu MC, Minchey SR, Cullis PR, Madden TD, et al. Unusual lipid structures selectively reduce the toxicity of amphotericin B. Proc Natl Acad Sci USA 1988; 85:6122-6.
21. Adler-Moore J, Proffitt RT. AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience. J Antimicrob Chemother 2002; 49 Suppl 1:21-30.
22. Sociedad Española de Medicina Intensiva, Crítica y Unidades Coronarias. Grupo de Trabajo de Enfermedades Infecciosas. Estudio Nacional de Vigilancia de Infección Nosocomial en Servicios de Medicina Intensiva (ENVIN-HELICS). En: http://hws.vhebron.net/envin-helics/ (Ultima entrada, 21 de noviembre 2011)
23. Álvarez-Lerma F, Rialp G, Nieto M, Aragón C, Puente T, Ausín I. Liposomal amphotericin B in intensive care unit patients previously treated with fluconazole: a retrospective, efficacy and safety multi-centre study. Abstract number: P1740. Clin Microbiol Infect 2009; 15 (Suppl s4): s499.